门冬胰岛素联合地特胰岛素与胰岛素泵对2型糖尿病强化治疗对比的研究

Comparison research on insulin aspart combined with insulin detemir versus continuous subcutaneous insulin infusion (CSII) in newly diagnosed type 2 diabetic patients

目的评价门冬胰岛素联合地特胰岛素与胰岛素泵持续皮下输注对新诊断T2DM患者的有效性和安全性。方法 94例新诊断的T2DM患者分别使用门冬胰岛素联合地特胰岛素(A组)和胰岛素泵持续皮下输注(B组)强化治疗方案,观察治疗前后的FPG、2hPG、FC-P、2hC-P、血糖达标时间、达标时胰岛素用量及低血糖发生率。结果治疗2周后,两组FPG、2hPG均较基线显著降低,而血糖达标时间、达标时胰岛素用量、低血糖发生率差异无统计学意义;两组FC-P治疗前为(0.69±0.13)、(0.81±0.15),治疗后为(1.3±0.2),(1.50±0.15),2hC-P治疗前为(1.62±0.16)、(1.44±0.17),治疗后为(3.80±0.80),(3.50±1.21),治疗前后差异均有统计学意义(P均<0.05)。结论对于新诊断的T2DM患者,与胰岛素泵持续皮下输注方案比较,门冬胰岛素联合地特胰岛素可安全、有效地控制血糖,恢复胰岛β细胞功能。

Objective To evaluate the efficacy and safety of insulin aspart combined with insulin detemir versus insulin pump therapy for newly diagnosed type 2 diabetic patients.Methods All 94 newly diagnosed type 2 diabetic patients were randomized into two groups,one treated by insulin aspart before 3 meals combined with insulin detemir at bedtime（group A）,and the another treated by insulin pump（group B）.FPG,2 hPG,FC-P,2 hC-P,time of glycemic control,dosage of insulin,and incidence of hypoglycemia were observed at the baseline and the end of the trail.Results After a 2-week treatment,the levels of FPG and 2 hPG decreased significantly from baseline in the two groups,while there was no significant difference between the two groups in time of glycemic control,dosage of insulin,and incidence of hypoglycemia.The increment of levels of FC-P in two groups before treatment：（0.69±0.13） and（0.81±0.15）,after treatment：（1.3±0.2） and（1.5±0.15） and 2 hC-P before treatment：（1.62±0.16） and（1.44±0.17）,after treatment：（3.8±0.80） and（3.5±1.21） was significant in statistics（all P〈0.05）.Conclusions For the newly diagnosed type 2 diabetic patients,treatment with insulin aspart combined with insulin detemir improves β-cell functions through a good glycemic control with the same efficacy and safety as insulin pump